REG - AstraZeneca PLC - Enhertu approved in EU for HER2-positive mBC

AstraZenecaAnnouncement

19/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220719:nRSS9426Sa&default-theme=true

RNS Number : 9426S  AstraZeneca PLC  19 July 2022

19 July 2022 07:00 BST

 

Enhertu approved in the EU for patients with HER2-positive metastatic breast
cancer treated with one or more prior anti-HER2-based regimens

 

Approval broadens indication for AstraZeneca and Daiichi Sankyo's Enhertu
across Europe to earlier use in HER2-positive metastatic breast cancer

 

Based on ground-breaking DESTINY-Breast03 results in which Enhertu
demonstrated a 72% reduction in the risk of disease progression or death vs.
trastuzumab emtansine (T-DM1)

 

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been
approved in the European Union (EU) as a monotherapy for the treatment of
adult patients with unresectable or metastatic HER2-positive breast cancer who
have received one or more prior anti-HER2-based regimens.

 

Enhertu is a specifically engineered HER2-directed antibody drug conjugate
(ADC) being jointly developed and commercialised by AstraZeneca and Daiichi
Sankyo.

 

The approval by the European Commission (EC) follows the positive opinion
(https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/enhertu-recommended-for-breast-cancer-eu-approval.html)
of the Committee for Medicinal Products for Human Use and is based on results
from the DESTINY-Breast03 Phase III trial, which were published in The New
England Journal of Medicine
(https://www.nejm.org/doi/full/10.1056/NEJMoa2115022?query=featured_home) .(1)
In the trial, Enhertu reduced the risk of disease progression or death by 72%
versus trastuzumab emtansine (T-DM1) (hazard ratio  HR  0.28; 95% confidence
interval  CI  0.22-0.37; p<0.000001) in patients with HER2-positive
unresectable and/or metastatic breast cancer previously treated with
trastuzumab and a taxane.

 

In Europe, more than 530,000 patients are diagnosed with breast cancer each
year.(2) Approximately one in five patients with breast cancer are considered
HER2-positive.(3) Despite initial treatment with trastuzumab, pertuzumab and a
taxane, patients with HER2-positive metastatic breast cancer will often
experience disease progression.(4,5)

 

Javier Cortés, MD, PhD, Head, International Breast Cancer Center (IBCC),
Barcelona, Spain, said: "This approval is an important milestone for patients
and clinicians in Europe, since previously treated patients with HER2-positive
metastatic breast cancer typically experience disease progression in less than
a year with historical standard of care treatment. In the DESTINY-Breast03
trial, the time to progression was extended well beyond a year for patients
receiving Enhertu, illustrating the potential for this medicine to set a new
benchmark in the treatment of HER2-positive metastatic breast cancer."

 

Dave Fredrickson, Executive Vice President, Oncology Business Unit,
AstraZeneca, said: "With this approval, patients across Europe with
HER2-positive metastatic breast cancer will have the opportunity to be treated
with Enhertu even earlier in the treatment of their disease, improving their
chance for better outcomes beyond what we can already offer patients treated
in later-line settings. Today's news is a further step in achieving our vision
to continuously bring the transformative potential of Enhertu to patients as
early as possible in their treatment to improve cancer outcomes."

 

Ken Keller, Global Head of Oncology Business, and President and CEO, Daiichi
Sankyo, Inc., said: "We believe there is a significant need to transform
outcomes for patients with HER2-positive metastatic breast cancer in Europe.
In DESTINY-Breast03, treatment with Enhertu demonstrated superior
progression-free survival and a doubling of the response rate compared to
another HER2-directed ADC. With this approval we are now able to offer
patients with HER2-positive metastatic breast cancer another option earlier in
their treatment."

 

Additional results from the DESTINY-Breast03 Phase III trial showed that in
the secondary endpoint of overall survival (OS), there was a strong trend
towards improved OS with Enhertu (HR 0.55; 95% CI 0.36-0.86), however this
analysis is not yet mature and further follow-up is ongoing. Nearly all
patients (96.1%) treated with Enhertu were alive at nine months compared to
91.3% of patients treated with T-DM1. Confirmed objective response rate (ORR)
was more than doubled in the Enhertu arm versus the T-DM1 arm (79.7% vs.
34.2%).

 

The safety of Enhertu has been evaluated in a pooled analysis of 573 patients
across multiple tumour types who had received at least one dose of Enhertu
(5.4 mg/kg) in clinical trials. The most common adverse reactions were nausea
(77.0%), fatigue (57.2%), vomiting (46.8%), alopecia (38.0%) and neutropenia
(34.6%). Cases of interstitial lung disease (ILD) or pneumonitis were reported
in 12.0% of patients. Most ILD cases were Grade 1 (2.6%) and Grade 2 (7.3%).
Grade 3 cases occurred in 0.7% of patients, no Grade 4 cases occurred, and
Grade 5 cases occurred in 1.4% of patients.

 

Based on the results of DESTINY-Breast03, the European Society for Medical
Oncology Clinical Practice Guidelines were updated in October 2021 to
recommend Enhertu for use as the preferred second-line therapy for patients
with HER2-positive metastatic breast cancer following progression with a
taxane and trastuzumab.(6)

( )

As part of this approval, the EC has also extended the market protection
period for Enhertu in this setting by one extra year based on the significant
clinical benefit compared to existing approved therapies.

 

Notes

 

Financial considerations

Following EU approval, an amount of $75m is due from AstraZeneca to Daiichi
Sankyo as a milestone payment in 2nd-line HER2-positive metastatic breast
cancer. The milestone will be capitalised as an addition to the upfront
payment made by AstraZeneca to Daiichi Sankyo in 2019 and subsequent
capitalised milestones, and will be amortised through the profit and loss
statement.

 

Sales of Enhertu in most EU territories are recognised by Daiichi Sankyo.
AstraZeneca reports its share of gross profit margin from Enhertu sales in
those territories as collaboration revenue in the Company's financial
statements. AstraZeneca will record product sales in respect of sales made in
territories where AstraZeneca is the selling party.

 

Further details on the financial arrangements were set out in the March 2019
announcement
(https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-and-daiichi-sankyo-enter-collaboration-for-novel-her-2-targeting-antibody-drug-conjugate.html)
of the collaboration.

 

HER2-positive breast cancer

Breast cancer is the most common cancer and is one of the leading causes of
cancer-related deaths worldwide.(7) More than two million patients were
diagnosed with breast cancer in 2020, with nearly 685,000 deaths globally.(7)
In Europe, more than 530,000 patients are diagnosed with breast cancer each
year.(2) Approximately one in five patients with breast cancer are considered
HER2-positive.(3)

( )

HER2 is a tyrosine kinase receptor, growth-promoting protein expressed on the
surface of many types of tumours including breast, gastric, lung and
colorectal cancers.(8) HER2 protein overexpression may occur as a result of
HER2 gene amplification and is often associated with aggressive disease and
poor prognosis in breast cancer.(9)

 

Despite initial treatment with trastuzumab, pertuzumab and a taxane, patients
with HER2-positive metastatic breast cancer will often experience disease
progression.(4,5) More treatment options are needed to further delay
progression and extend survival.(4,10,11)

 

DESTINY-Breast03

DESTINY-Breast03 is a global, head-to-head, randomised, open-label,
registrational Phase III trial evaluating the efficacy and safety of Enhertu
(5.4mg/kg) versus T-DM1 in patients with HER2-positive unresectable and/or
metastatic breast cancer previously treated with trastuzumab and a taxane.

 

The primary efficacy endpoint of DESTINY-Breast03 is PFS based on blinded
independent central review. OS is a key secondary efficacy outcome measure.
Secondary efficacy endpoints include ORR, duration of response and PFS based
on investigator assessment.

 

DESTINY-Breast03 enrolled 524 patients at multiple sites in Asia, Europe,
North America, Oceania and South America. Results from DESTINY-Breast03 have
been published in The New England Journal of Medicine
(https://www.nejm.org/doi/full/10.1056/NEJMoa2115022?query=featured_home) .(1)
For more information about the trial, visit ClinicalTrials.gov
(https://clinicaltrials.gov/ct2/show/NCT03529110) .

 

Enhertu

Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo's proprietary
DXd ADC technology, Enhertu is the lead ADC in the oncology portfolio of
Daiichi Sankyo and the most advanced programme in AstraZeneca's ADC scientific
platform. Enhertu consists of a HER2 monoclonal antibody attached to a
topoisomerase I inhibitor payload, an exatecan derivative, via a stable
tetrapeptide-based cleavable linker.

 

Enhertu (5.4mg/kg) is approved in more than 30 countries for the treatment of
adult patients with unresectable or metastatic HER2-positive breast cancer who
have received a (or one or more) prior anti-HER2-based regimen either in the
metastatic setting, or in the neoadjuvant or adjuvant setting and have
developed disease recurrence during or within six months of completing
therapy, based on the results from the DESTINY-Breast03 trial.

 

Enhertu (5.4mg/kg) is also approved in several countries for the treatment of
adult patients with unresectable or metastatic HER2-positive breast cancer who
have received two or more prior anti-HER2-based regimens based on the results
from the DESTINY-Breast01 trial.

 

Enhertu (6.4mg/kg) is approved in several countries for the treatment of adult
patients with locally advanced or metastatic HER2-positive gastric or
gastroesophageal junction (GEJ) adenocarcinoma who have received a prior
trastuzumab-based regimen based on the results from the DESTINY-Gastric01
trial.

 

Enhertu development programme

A comprehensive development programme is underway globally, evaluating the
efficacy and safety of Enhertu monotherapy across multiple HER2-targetable
cancers, including breast, gastric, lung and colorectal cancers. Trials in
combination with other anticancer treatments, such as immunotherapy, are also
underway.

 

Regulatory applications for Enhertu are currently under review in China, Japan
and several other countries for the treatment of adult patients with
unresectable or metastatic HER2-positive breast cancer who have received a
prior anti-HER2-based regimen based on the results from the DESTINY-Breast03
trial.

 

Enhertu is under review in Europe for the treatment of adult patients with
unresectable or metastatic HER2-low (immunohistochemistry (IHC) 1+ or IHC 2+/
in-situ hybridisation (ISH)-negative) breast cancer who have received a prior
systemic therapy in the metastatic setting or developed disease recurrence
during or within six months of completing adjuvant chemotherapy, based on the
results from the DESTINY-Breast04 trial. Patients with hormone receptor (HR)
positive breast cancer must additionally have received or be ineligible for
endocrine therapy.

 

Enhertu is also currently under review in the US for the treatment of adult
patients with unresectable or metastatic non-small cell lung cancer (NSCLC)
whose tumours have a HER2 (ERBB2) mutation and who have received a prior
systemic therapy based on the results of the DESTINY-Lung01 trial, and in
Europe for the treatment of adult patients with locally advanced or metastatic
HER2-positive gastric or GEJ adenocarcinoma who have received a prior
anti-HER2-based regimen based on the DESTINY-Gastric01 and DESTINY-Gastric02
trials.

 

Enhertu was granted Breakthrough Therapy Designation
(https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-btd-her2-low-breast-cancer.html)
in the US for the treatment of adult patients with unresectable or metastatic
HER2-low (IHC 1+ or IHC 2+/ISH-negative) breast cancer who have received a
prior systemic therapy in the metastatic setting or developed disease
recurrence during or within six months of completing adjuvant chemotherapy,
based on the results of the DESTINY-Breast04 trial. Patients with HR-positive
breast cancer should additionally have received or be ineligible for endocrine
therapy.

Daiichi Sankyo collaboration

Daiichi Sankyo Company, Limited (TSE:4568) [referred to as Daiichi Sankyo] and
AstraZeneca entered into a global collaboration to jointly develop and
commercialise Enhertu
(https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-and-daiichi-sankyo-enter-collaboration-for-novel-her-2-targeting-antibody-drug-conjugate.html)
(a HER2-directed ADC) in March 2019, and datopotamab deruxtecan
(https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-daiichi-sankyo-enter-collaboration-to-develop-and-commercialise-new-antibody-drug-conjugate.html)
(DS-1062; a TROP2-directed ADC) in July 2020, except in Japan where Daiichi
Sankyo maintains exclusive rights. Daiichi Sankyo is responsible for
manufacturing and supply of Enhertu and datopotamab deruxtecan.

 

AstraZeneca in breast cancer

Driven by a growing understanding of breast cancer biology, AstraZeneca is
starting to challenge, and redefine, the current clinical paradigm for how
breast cancer is classified and treated to deliver even more effective
treatments to patients in need - with the bold ambition to one day eliminate
breast cancer as a cause of death.

 

AstraZeneca has a comprehensive portfolio of approved and promising compounds
in development that leverage different mechanisms of action to address the
biologically diverse breast cancer tumour environment.

 

AstraZeneca aims to continue to transform outcomes for HR-positive breast
cancer with foundational medicines Faslodex (fulvestrant) and Zoladex
(goserelin) and the next-generation oral selective oestrogen receptor degrader
(SERD) and potential new medicine camizestrant.

 

PARP inhibitor Lynparza (olaparib) is a targeted treatment option that has
been studied in HER2-negative early and metastatic breast cancer patients with
an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co., Inc. in the
US and Canada) continue to research Lynparza in metastatic breast cancer
patients with an inherited BRCA mutation and are exploring new opportunities
to treat these patients earlier in their disease.

 

Building on the initial approvals of Enhertu, a HER2-directed ADC, in
previously treated HER2-positive metastatic breast cancer, AstraZeneca and
Daiichi Sankyo are exploring its potential in earlier lines of treatment and
in new breast cancer settings.

 

To bring much needed treatment options to patients with triple-negative breast
cancer, an aggressive form of breast cancer, AstraZeneca is testing
immunotherapy Imfinzi (durvalumab) in combination with other oncology
medicines, including Lynparza and Enhertu, evaluating the potential of AKT
kinase inhibitor, capivasertib, in combination with chemotherapy, and
collaborating with Daiichi Sankyo to explore the potential of TROP2-directed
ADC, datopotamab deruxtecan.

 

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide
cures for cancer in every form, following the science to understand cancer and
all its complexities to discover, develop and deliver life-changing medicines
to patients.

 

The Company's focus is on some of the most challenging cancers. It is through
persistent innovation that AstraZeneca has built one of the most diverse
portfolios and pipelines in the industry, with the potential to catalyse
changes in the practice of medicine and transform the patient experience.

 

AstraZeneca has the vision to redefine cancer care and, one day, eliminate
cancer as a cause of death.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

References

1.   Cortes J, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine
for Breast Cancer. N Engl J Med. 2022; 386:1143-1154.

2.   Globocan 2020. Europe Fact Sheets. Available at:
https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf
(https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf)
. Last accessed: July 2022.

3.   Ahn S, et al. HER2 status in breast cancer: changes in guidelines and
complicating factors for interpretation. J Pathol Transl Med. 2020; 54(1):
34-44.

4.   Barok M, et al. Trastuzumab emtansine: mechanism of action and drug
resistance. Breast Cancer Res. 2014; 16(2):209.

5.   Nader-Marta G, et al. How we treat patients with metastatic
HER2-positive breast cancer. ESMO Open. 2022; 7:1.

6.   Gennari A, et al. ESMO Clinical Practice Guideline for the diagnosis,
staging and treatment of patients with metastatic breast cancer. Available at:
https://www.annalsofoncology.org/article/S0923-7534(21)04498-7/pdf. Last
accessed: July 2022.

7.   Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of
Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J
Clin. 2021; 10.3322/caac.21660.

8.   Iqbal N, et al. Human Epidermal Growth Factor Receptor 2 (HER2) in
Cancers: Overexpression and Therapeutic Implications. Mol Biol Int.
2014;852748.

9.   Pillai R, et al. HER2 mutations in lung adenocarcinomas: A report from
the Lung Cancer Mutation Consortium. Cancer. 2017;1;123(21):4099-4105.

10.  Mounsey L, et al. Changing Natural History of HER2-Positive Breast
Cancer Metastatic to the Brain in the Era of New Targeted Therapies. Clin
Breast Cancer. 2018; 18(1):29-37.

11.  Martinez-S Sáez O, et al. Current and Future Management of
HER2-Positive Metastatic Breast Cancer. JCO Oncol Pract. 2021.
10.1200/OP.21.00172.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEASXNFFLAEEA